BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30863045)

  • 1. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.
    Hoogendoorn M; Corro Ramos I; Baldwin M; Luciani L; Fabron C; Detournay B; Rutten-van Mölken MPMH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():447-456. PubMed ID: 30863045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
    Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
    van Boven JF; Kocks JW; Postma MJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study.
    Hoogendoorn M; Corro Ramos I; Soulard S; Cook J; Soini E; Paulsson E; Rutten-van Mölken M
    BMJ Open; 2021 Aug; 11(8):e049675. PubMed ID: 34348953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
    Singh D; Gaga M; Schmidt O; Bjermer L; Grönke L; Voß F; Ferguson GT
    Respir Res; 2016 Jun; 17(1):73. PubMed ID: 27316465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of baseline symptom burden on treatment response in COPD.
    Martinez FJ; Abrahams RA; Ferguson GT; Bjermer L; Grönke L; Voß F; Singh D
    Int J Chron Obstruct Pulmon Dis; 2019; 14():181-194. PubMed ID: 30655665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study.
    Ichinose M; Nishimura M; Akimoto M; Kurotori Y; Zhao Y; de la Hoz A; Mishima M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2147-2156. PubMed ID: 30034230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO
    Rabe KF; Chalmers JD; Miravitlles M; Kocks JWH; Tsiligianni I; de la Hoz A; Xue W; Singh D; Ferguson GT; Wedzicha J
    Adv Ther; 2021 Jan; 38(1):579-593. PubMed ID: 33175291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO
    Ferguson GT; Karpel JP; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO
    Wedzicha JA; Buhl R; Singh D; Vogelmeier CF; de la Hoz A; Xue W; Anzueto A; Calverley PMA
    Adv Ther; 2020 Oct; 37(10):4266-4279. PubMed ID: 32776202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease.
    Palli SR; Buikema AR; DuCharme M; Frazer M; Kaila S; Juday T
    J Comp Eff Res; 2019 Nov; 8(15):1299-1316. PubMed ID: 31559852
    [No Abstract]   [Full Text] [Related]  

  • 13. Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.
    Bai C; Ichinose M; Lee SH; Lee KH; Jöns O; Bothner U; Zhao Y; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3329-3339. PubMed ID: 29200840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
    Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.
    Ichinose M; Minakata Y; Motegi T; Ueki J; Gon Y; Seki T; Anzai T; Nakamura S; Hirata K
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1407-1419. PubMed ID: 29750027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
    Chan MC; Tan EC; Yang MC
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1079-1088. PubMed ID: 29670344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
    Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
    Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
    Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
    Derom E; Brusselle GG; Joos GF
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.